Status quo and identification efficiency of metabolic-associated fatty liver disease in patients with chronic hepatitis C
10.3969/j.issn.1006-2483.2026.05.031
- VernacularTitle:慢性丙型肝炎患者发生代谢相关脂肪性肝病现状及识别效能分析
- Author:
Yuejin CHEN
1
;
Peigen SHEN
2
;
Xinfeng HUANG
1
;
Yanhui LU
2
Author Information
1. Department of Disease Control and Prevention, the 909th Hospital (Southeast Hospital Affiliated with Xiamen University) Zhangzhou , Fujian 363000, China
2. Department of Infectious Diseases, the 909th Hospital (Southeast Hospital Affiliated with Xiamen University) Zhangzhou , Fujian 363000, China
- Publication Type:Journal Article
- Keywords:
Chronic hepatitis C;
Metabolic-associated fatty liver disease;
Liver function;
Lipid metabolism;
Prediction model
- From:
Journal of Public Health and Preventive Medicine
2026;37(5):145-149
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the status quo and identification efficiency of metabolic-associated fatty liver disease (MAFLD) in patients with chronic hepatitis C (CHC). Methods A total of 407 patients with CHC who were admitted to the hospital between January 2022 and January 2025 were collected as study subjects. According to whether MAFLD was newly diagnosed during the study period, all enrolled patients were classified into two groups, including MAFLD group (CHC with MAFLD, n=143) and CHC group (CHC, n=264). The general data [gender, age, place of residence, body mass index (BMI), systolic blood pressure, diastolic blood pressure, course of chronic hepatitis C (CHC), history of diabetes mellitus], liver function indicators [alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transferase (GGT)], glucose metabolism indicators [fasting blood glucose (FBG), fasting insulin (FINS), hemoglobin A1c (HbA1c), homeostasis model assessment of insulin resistance (HOMA-IR)], lipid metabolism indicators [total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C)], serum specific protein markers {serum 25-hydroxyvitamin D [25(OH)D], adipocyte fatty acid binding protein (A-FABP), retinol binding protein 4 (RBP4), sterol regulatory element binding protein-1c (SREBP-1c)}were compared between both groups. Binary logistic regression analysis was performed for multivariate regression analysis. ROC curve was utilized to evaluate the identification value. Results The levels of ALT, AST, ALP, GGT, FBG, FINS, HbA1c, TC, TG, LDL-C, A-FABP, RBP4 and SREBP-1c in the MAFLD group were higher than those in the CHC group (P<0.05) while the levels of HDL-C and 25(OH)D were lower compared to the CHC group (P<0.05). Multivariate logistic regression analysis results suggested that TG, 25(OH)D, RBP4, HbA1c and HOMA-IR were independent related factors influencing MAFLD occurrence (P<0.05). ROC curve analysis results revealed that the identification efficiency of combined prediction (AUC=0.854, 95% CI : 0.812-0.887)was better than that of TG (AUC=0.653, 95% CI: 0.607-0.720), 25(OH)D (AUC=0.685, 95% CI: 0.607-0.715), RBP4 (AUC=0.649, 95%CI: 0.633-0.741), HbA1c (AUC=0.718, 95% CI: 0.657-0.755) or HOMA-IR (AUC=0.726, 95% CI: 0.654-0.757), and combined prediction had the best identification efficiency (P<0.05). Conclusion CHC patients with MAFLD have significant metabolic disorders and changes in specific protein markers. TG, 25(OH)D, RBP4, HbA1c and HOMA-IR are independent related factors, and combined prediction model of multiple indicators exhibits good identification efficiency.
